United States News All stories

Assembly Biosciences (NASDAQ:ASMB) announced plans to expand the clinical development framework for its experimental compound ABI-6250, pushing the asset beyond its initial virology target into chronic cholestatic liver conditions.

Enhertu (trastuzumab deruxtecan) moved a step closer to a milestone regulatory approval in Europe, securing a positive recommendation from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) as a tumor-agnostic treatment for advanced solid malignancies.

AbbVie (NYSE:ABBV) announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the approval of Maviret (glecaprevir/pibrentasvir) for the treatment of acute hepatitis C virus (HCV) infection.

Global Ship Lease (NYSE:GSL) reported elevated top-line growth and resilient cash generation for the first quarter of 2026, insulating its balance sheet from broader maritime macro-volatility through defensive multi-year charter coverage.

BioLineRx (NASDAQ:BLRX) and Hemispherian announced that two abstracts featuring their experimental oncology compound, GLIX1, will be published at the upcoming American Society of Clinical Oncology (ASCO) 2026 Annual Meeting.

ImmunityBio (NASDAQ:IBRX) announced new survey data highlighting the highly individualized treatment preferences and quality-of-life priorities of patients navigating high-risk non-muscle-invasive bladder cancer (NMIBC).

AC Immune (NASDAQ:ACIU) announced positive preliminary Phase 1 clinical data for its experimental brain imaging agent, ACI-19626, expanding its diagnostic reach into amyotrophic lateral sclerosis (ALS).

Booz Allen Hamilton Holding (NYSE:BAH) announced its preliminary financial results for the fourth quarter of fiscal year 2026, delivering an uptick in profitability and backlog expansion despite a contraction in top-line revenue.

BJ’s Wholesale Club Holdings (NYSE:BJ) reported a slight decline in first-quarter net income, as aggressive pricing strategies and rising overhead from footprint expansion offset resilient gains in membership fee revenue.

LyondellBasell Industries (NYSE:LYB) announced today that its board of directors has declared a quarterly cash dividend of $0.69 per share.

Crude oil prices fluctuated as conflicting political statements clouded the timeline for a resolution over the Strait of Hormuz, offsetting pressure from rapidly depleting global stockpiles.

So-Young International (NASDAQ:SY) posted record first-quarter revenue that surpassed internal targets, propelled by a surge in consumer demand across its brick-and-mortar medical aesthetic centers, even as aggressive expansion spending weighed on near-term profitability.

Rocket Lab (NASDAQ:RKLB) has been awarded a $90 million contract by the U.S. Space Force’s Space Systems Command to design, build, and operate two geostationary orbit (GEO) satellites, signaling an expansion of the company’s manufacturing footprint into higher-altitude national security systems.

Ascentage Pharma (NASDAQ:AAPG) announced that abstracts for six of its clinical studies have been published ahead of the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, outlining early-phase therapeutic activity across its core pipeline of targeted oncology candidates.

HUTCHMED (NASDAQ:HCM) announced that its targeted oncology candidate, savolitinib, achieved its primary endpoint in a registration-enabling Phase II trial for patients with a specific type of advanced gastric cancer.

Teva Pharmaceutical Industries (NYSE:TEVA) and Medincell announced Thursday that the European Medicines Agency has accepted their Marketing Authorization Application for TEV-749, an investigational long-acting injectable formulation designed to treat adults living with schizophrenia.

Gogoro (NASDAQ:GGR) reported a significantly narrower net loss and positive operating cash flow for the first quarter of 2026, navigating a mixed operational landscape where expanding energy subscription revenues offset soft consumer hardware demand.

NIO (NYSE:NIO) reported a 112.2% surge in first-quarter revenue for 2026, driven by a near-doubling of vehicle deliveries and vastly improved manufacturing margins that pushed the company’s adjusted net results into profitability.

Parker Hannifin (NYSE:PH) has signed a definitive agreement to acquire CIRCOR Aerospace from KKR and CIRCOR International, Inc. for a cash purchase price of $2.55 billion, marking a significant expansion for the industrial giant's flight-critical components division.

Hovnanian Enterprises (NYSE:HOV) reported a small net loss for its second fiscal quarter that nevertheless came in ahead of internal operating guidance, as resilient homebuyer traffic helped the national homebuilder mitigate ongoing margin compression and affordability hurdles.

United Maritime (NASDAQ:USEA) reported a sharp reduction in its first-quarter net loss alongside a return to positive adjusted earnings, driven by a strategic fleet reallocation into the higher-earning Capesize dry bulk sector and substantial capital recycling.

Cosmos Health (NASDAQ:COSM) generated record revenue in the first quarter of 2026, driven by sustained distribution gains and market expansions, even as a shifting business mix and operational investments weighed on bottom-line profitability.

Williams-Sonoma (NYSE:WSM) reported solid top-line momentum for its first fiscal quarter, driven by positive comparable brand revenue across its portfolio, though elevated import tariff expenses weighed on the retailer's gross margins.

Immix Biopharma (NASDAQ:IMMX) announced a highly favorable interim update from its ongoing registrational Phase 2 NEXICART-2 clinical trial, showing that its investigational CAR-T cell therapy, NXC-201, achieved a 95% complete response rate in patients with relapsed or refractory AL Amyloidosis.